1 421

Cited 4 times in

Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B.

 Yong Kwang Park  ;  Jung Min Lee  ;  Do Young Kim  ;  Hye Young Chang  ;  Ja Kyung Kim  ;  Chun Kyon Lee  ;  Jun Yong Park  ;  Sang Hoon Ahn  ;  Kwan Sik Lee  ;  Kwang Hyub Han 
 DIGESTIVE DISEASES AND SCIENCES, Vol.55(7) : 2043-2048, 2010 
Journal Title
Issue Date
Adult ; Analysis of Variance ; Case-Control Studies ; Confidence Intervals ; Disease Progression ; Female ; Follow-Up Studies ; Gene Expression Regulation ; Genotype ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy* ; Hepatitis B, Chronic/genetics* ; Humans ; Lamivudine/therapeutic use* ; Liver Function Tests ; Male ; Middle Aged ; Multivariate Analysis ; Odds Ratio ; Polymorphism, Genetic* ; Probability ; Promoter Regions, Genetic/drug effects* ; Reference Values ; Risk Assessment ; Severity of Illness Index ; Treatment Failure ; Treatment Outcome ; Tumor Necrosis Factor-alpha/genetics* ; Tumor Necrosis Factor-alpha/metabolism ; Young Adult
Hepatitis B virus ; Lamivudine ; Tumor necrosis factor-alpha ; Single nucleotide polymorphism
BACKGROUND: TNF-alpha promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. AIMS: We investigated whether polymorphisms of TNF-alpha promoter at position -308 or -238 had associations with the response to lamivudine treatment. METHODS: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-alpha promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. RESULTS: The numbers of A allelic polymorphism of TNF-alpha promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). CONCLUSIONS: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-alpha promoter at position -238.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Medical Research Center (임상의학연구센터) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영)
Kim, Ja Kyung(김자경) ORCID logo https://orcid.org/0000-0001-5025-6846
Park, Yong Kwang(박용광)
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Kwan Sik(이관식) ORCID logo https://orcid.org/0000-0002-3672-1198
Lee, Jung Min(이중민)
Chang, Hye Young(장혜영)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.